Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Envoplakin (EVPL) is a member of the plakin family of structural proteins that is integral to the formation and maintenance of the cornified envelope in keratinocytes, a key component of the skin barrier. It is expressed in the epidermal cornified envelope and may act as a link between desmosomes (cell-cell junctions) and intermediate filaments, contributing to the structural integrity of stratified squamous epithelia. The EVPL gene is located on chromosome 17q25. Deletion of this gene has been linked to both familial and sporadic forms of oesophageal squamous cell carcinoma. Additionally, patients with paraneoplastic pemphigus, an autoimmune blistering disorder, produce antibodies against envoplakin, implicating it in autoimmune pathology[1][5]. Its main paralog is periplakin (PPL), with which it can interact[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Envoplakin (EVPL) (EVPL).